MDC — Medlab Clinical Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -993.58% | ||
| Operating Margin | -14833.74% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.92 | 0.76 | 1.33 | 0.94 | 0.01 | 6.8 | n/a | -71.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company. The Company specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals with the objective of empowering patients with chronic diseases and mental health conditions and enhancing their lives. Its drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress. It also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. It is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas.
Directors
- Michael Jack Hall NEC
- Sean Hall CEO
- Kerem Kaya CFO
- Samantha Coulson OTH
- Robert Jensen OTH
- Naresh Patel OTH
- David Rutolo OTH
- Luis Vitetta OTH
- Drew Townsend SEC
- Cheryl Maley NID
- Laurence McAllister NID
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- April 17th, 2014
- Public Since
- July 14th, 2015
- No. of Shareholders
- 4,952
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 2,283,502
- Address
- Units 5 And 6 11 Lord Street Botany, ALEXANDRIA, 2019
- Web
- https://www.medlab.co/
- Phone
- +61 281880311
- Contact
- Laine Yonker
- Auditors
- MNSA Pty Ltd
Upcoming Events for MDC
Similar to MDC
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Medlab Clinical share price?
As of Today at 20:57 UTC, shares in Medlab Clinical are trading at AU$6.60. This share price information is delayed by 15 minutes.
How has the Medlab Clinical share price performed this year?
Shares in Medlab Clinical last closed at AU$6.60 and the price had moved by -64.8% over the past 365 days. In terms of relative price strength the Medlab Clinical share price has underperformed the ASX All Ordinaries Index by -67.48% over the past year.
What are the analyst and broker recommendations for Medlab Clinical?
The overall consensus recommendation for Medlab Clinical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medlab Clinical dividend yield?
Medlab Clinical does not currently pay a dividend.
Does Medlab Clinical pay a dividend?
Medlab Clinical does not currently pay a dividend.
When does Medlab Clinical next pay dividends?
Medlab Clinical does not currently pay a dividend.
How do I buy Medlab Clinical shares?
To buy shares in Medlab Clinical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medlab Clinical?
As of the previous close price of AU$6.60, shares in Medlab Clinical had a market capitalisation of .
Where are Medlab Clinical shares listed?
Here are the trading details for Medlab Clinical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MDC
What kind of share is Medlab Clinical?
Based on an overall assessment of its quality, value and momentum Medlab Clinical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medlab Clinical share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Medlab Clinical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medlab Clinical. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -50.82%.
As of the last closing price of AU$6.60, shares in Medlab Clinical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medlab Clinical PE Ratio?
The Medlab Clinical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$6.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medlab Clinical?
Medlab Clinical's management team is headed by:
- Michael Jack Hall - NEC
- Sean Hall - CEO
- Kerem Kaya - CFO
- Samantha Coulson - OTH
- Robert Jensen - OTH
- Naresh Patel - OTH
- David Rutolo - OTH
- Luis Vitetta - OTH
- Drew Townsend - SEC
- Cheryl Maley - NID
- Laurence McAllister - NID